Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.59−0.67 (-6.53%)
Close on Nov 12, 2026Market cap $159.01MP/E –Yield –
Sutro Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Sutro Biopharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$129.44M. For fiscal 2025 it was -$177.23M. The highest annual figure on record is $12.68M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$177.23M | – |
| FY2024 | Dec 31, 2024 | -$191.54M | – |
| FY2023 | Dec 31, 2023 | -$111.62M | -3245.0% |
| FY2022 | Dec 31, 2022 | $3.55M | – |
| FY2021 | Dec 31, 2021 | -$81.68M | – |
| FY2020 | Dec 31, 2020 | -$67.80M | – |
| FY2019 | Dec 31, 2019 | -$65.02M | -612.7% |
| FY2018 | Dec 31, 2018 | $12.68M | – |
| FY2017 | Dec 31, 2017 | -$37.07M | – |
| FY2016 | Dec 31, 2016 | -$13.15M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$22.45M | – |
| Q2 FY2026 | Jun 30, 2026 | -$38.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$26.44M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.72M | -573.0% |
| Q1 FY2025 | Mar 31, 2025 | -$67.88M | – |
| Q4 FY2024 | Dec 31, 2024 | -$71.74M | -609.8% |
| Q3 FY2024 | Sep 30, 2024 | -$64.52M | – |
| Q2 FY2024 | Jun 30, 2024 | $9.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$64.74M | – |
| Q4 FY2023 | Dec 31, 2023 | $14.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.50M | -150.9% |
| Q2 FY2023 | Jun 30, 2023 | -$31.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$60.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.86M | – |
| Q3 FY2022 | Sep 30, 2022 | $65.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.88M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.73M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.16M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.12M | -133.9% |
| Q2 FY2019 | Jun 30, 2019 | -$15.60M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.15M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.94M | – |
| Q3 FY2018 | Sep 30, 2018 | $47.57M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.95M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.01M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.84M | – |
See a number that looks wrong?